Form 4: REGENXBIO CFO Exercises Stock Options, Acquires 20,041 Shares

REGENXBIO's Chief Financial Officer, Vittal Vasista, exercised stock options to acquire 20,041 shares of common stock at $3.76 per share on March 19, 2024.

Summary

• On March 19, 2024, Vittal Vasista, the Chief Financial Officer of REGENXBIO Inc., exercised employee stock options.
• This transaction resulted in the acquisition of 20,041 shares of REGENXBIO's common stock at a price of $3.76 per share.
• Following the transaction, Vasista directly owns 246,534 shares of REGENXBIO common stock.
• The stock options were granted previously and vested over time, with a portion vesting on May 19, 2016, and the remainder vesting in equal monthly installments over the subsequent 36 months.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Positives

• The CFO's decision to exercise stock options could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

This is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, primarily providing transparency to shareholders regarding executive stock ownership.

Key Dates